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Abstract
Objective: To evaluate the potential for injectable, permanent bone augmentation by
assessing the biocompatability and bioactivity of subperiosteal hydroxylapatite
(Radiesse) deposition in a rat model.
Methods: Fourteen adult Sprague Dawley rats were injected in the parietal skull with 0.2
ml of hydroxylapatite (10 animals) or a carrier gel control (4 animals), using a
subperiosteal injection technique on the right and a subcutaneous injection technique on
the left. At 1, 3, and 6 months, 3 rats (1 negative control, 2 variables) were sacrificed and
calvaria were harvested. At 12 months, the remaining 5 rats were sacrificed. After each
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harvest, the specimens were processed and then examined under both light and polarized
microscopy for new bone growth at the injection sites.
Results: The inflammatory response was limited with both hydroxylapatite and carrier
injections. Injectables were still present 12 months after the injection. New bone
formation was only seen when the injection was located deep to a disrupted periosteum
The odd of new bone formation was 48.949 times higher (95% CI (2.637, 3759.961), p
= 0.002) with subperiosteal hydroxylapatite injections compared to all other
combinations of injection plane and injectable.
Conclusion: This preliminary report of subperiosteal hydroxylapatite (Radiesse) injection
in a rat model has verified the biocompatibility of injectable hydroxylapatite at the bony
interface and suggests the potential for new bone formation.

Introduction
Craniofacial bony reconstruction can be broadly classified as either organic or
alloplastic. While autografts remain the gold standard, alloplastic bone substitutes have
been widely employed in order to eliminate donor site morbidity, reduce operative time,
and facilitate contouring. Presently, calcium phosphate cements (CPC), such as
hydroxylapatite (HA), are commonly used for the alloplastic repair of skull defects.
Favorable characteristics of CPC include customizability, isothermic setting,
biocompatability, and bioactivty (resorption is countered by new bone replacement).1
Because of the chemical properties pertaining to setting, open exposure is required
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to use CPC effectively, and thus the application of CPC is reserved for large defects, such
as those that result from tumor extirpation or extensive trauma. However, facial plastic
surgeons are often faced with smaller craniofacial deformities that are of aesthetic
concern to the patient but do not warrant the morbidity of open surgery. Examples would
include relatively minor traumatic bony injury and contour deficiencies from prior
surgery. With these defects in mind, the present study was designed to examine the
biologic characteristics of injectable HA (Radiesse, Bioform Medical, Inc., San Mateo,
CA, USA) when interfaced with bone. We hypothesized that the biocompatability and
bioactivity of subperiosteal HA injections would mirror those of the cement formulation,
making Radiesse potentially useful for the office-based correction of small craniofacial
deformities.

Methods
At the outset of this study, approval was obtained from the Institutional
Animal Care and Use Committee of Thomas Jefferson University. Fourteen adult
Sprague Dawley rats were first anesthetized with isofluorane via a mask apparatus and
then injected in the parietal skull with 0.2 ml of HA (10 animals) or a carrier gel
control (4 animals). In each rat, the left sided injection was performed just medial to
the auricle with a 23-gauge needle in a subcutaneous plane. On the right side of the
calvarium, a 20-gauge needle was first employed to elevate the periosteum, and then a
23-gauge needle was used to inject the material directly on to the underlying bone
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(again just medial to the auricle). Appropriate placement of the injection was reaffirmed grossly by mobilizing the scalp- the subcutaneous deposits were noted to
move with the scalp, while the subperiosteal deposits remained fixed.
Animals were subsequently sacrificed at four time points (1,3,6, and 12 months
after the initial injections) and calvaria were harvested for histologic analysis. Each of
the first 3 harvests included 2 rats from the HA group and 1 negative control from the
carrier gel group. The 12-month harvest again included 1 negative control as well as
the remaining 4 rats from the HA group. All of the harvested calvaria were shaved,
placed in 10% formalyn, and turned over to the Thomas Jefferson University
Department of Pathology.
Using a Mar-Med diamond band bone saw , a coronal section of each
calvarium was isolated using the auricles as landmarks. These coronal sections were
then sliced further in the sagittal plane to create 5 blocks of tissue, aproximately 2-3
mm in thickness, numbered 1-5 while moving right to left. In preparation for
microscopic analysis, the tissue sections were decalcified (using CalEx solution) over
a 2-day period for a total of 12 hours and then pressed and embedded in paraffin.
Finally, each block was cut with a Leica microtome to create 5-micron specimens.
All specimens were stained with hematoxylin and eosin. Under low power
magnification, the injectables were located and the surrounding tissue was examined.
Proper identification of the injectables was confirmed by examining and comparing
separate samples of the HA and carrier gel ex vivo (Figure 1). Polarized microscopy
was used to distinguish new (woven) bone from mature (lamellar) bone.
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Histologic findings were categorized into data tables that were then analyzed
statistically in consultation with the Thomas Jefferson University Department of
Biostatistics. Odds ratios, p values and 95% confidence intervals (CI) were calculated
using Fisher’s conditional maximum likelihood estimation. P values < 0.05 were
considered significant.

Results
Histologic data are summarized in Table 1. The inflammatory response to both
the HA and the carrier gel control was scant at all time points, regardless of the
location of the injection. While multinucleated giant cells were often present (Figure
2), only minimal fibrosis was noted in the specimens. As intended, all of the
subcutaneous injections were noted to be above an intact periosteum on histologic
review. Seven (2 carrier, 5 HA) out of 13 “subperiosteal” injections were found to be
deep to a disrupted periosteum, while the remaining 6 were noted to be in the
subcutaneous layer with an intact periosteum beneath. Of note, HA spherules could
not be found at the subcutaneous site for specimen 12 and at both injection sites for
specimen 13.
Reactive bone was not seen in the absence of periosteal disruption. In 1 of 2
rats with successful subperiosteal carrier injections, reactive bone was present at the
time of harvest. This rat, specimen 7, was sacrificed at 6 months (Figure 3). Reactive
bone was observed with subperiosteal HA injections in 4 out of 5 rats- specimen 2
from the 1 month harvest (Figure 4), specimen 5 from the 3 month harvest, and
specimens 12 and 14 from the 12 month harvest. Interestingly, mature lamellar bone
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was seen above the HA spherules in specimen 12, indicating osteointegration. (Figure
5)
In an attempt to analyze the effect of the injection plane (subcutaneous vs
subperiosteal) and the injectable (carrier vs HA) on new bone formation, histologic
data was re-organized as depicted in Table 2. The primary outcome measure of new
bone formation is presented in binary format for all 4 combinations of injection plane
and injectable. Of note, injections that were intended to be subperiosteal but were
found to be subcutaneous on histologic review were considered “subcutaneous” (n =
6) for the purposes of statistical analysis. In doing so, we assumed that two
subcutaneous injections in one rat were independent of one another. Furthermore, any
specimen without an identifiable injectable (subcutaneous injection site in specimen
12 and both sites in specimen 13) were excluded. Therefore, out of 28 possible
injections (subcutaneous and subperiosteal sites in 14 rats), 25 were considered for the
analysis (18 subcutaneous sites, 7 subperiosteal sites).
The odd of new bone formation in the subperiosteal HA injection group was
48.949 times higher than the other 3 combinations in aggregate (95% CI (2.637,
3759.961), p = 0.002). The marginal effect of subperiosteal injection was also
significant, but a discrete odds ratio could not be computed due to the zero-count cells
in the subcutaneous groups (95% CI (4.068, infinity), p < 0.001). The marginal effect
of HA, however, was not significant. The odd of new bone formation with HA
injection regardless of injection plane was only 2.095 times higher than that of the
carrier injections (95% CI (0.161, 120.910), p = 1.000).
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Discussion
Minor deformities of the craniofacial skeleton can be quite bothersome
aesthetically to patients. Unfortunately, the morbidity of surgical correction often
deters patients from seeking treatment. Radiesse provides an intriguing option for
these patients as its main biologic constituent, HA, has been used for over 2 decades in
other formulations (initially cermaic, more recently cement) for open craniofacial
reconstruction.2 It consists of 30% calcium HA microspheres (25-45 μm) identical to
the mineral portion of bone in a carrier gel (1.3% sodium carboxymethylcellulose,
6.4% glycerin, and 36.6% sterile water) that provides cohesiveness.
FDA-approved for the treatment of HIV-related lipoatrophy and moderate to
deep nasolabial folds, Radiesse is well-established in facial plastic surgery for soft
tissue augmentation.3,4 Over the years, various studies have confirmed its safety,
longevity and bioactivity (specifically the stimulation of new collagen deposition)
when injected subcutaneously.5-7 Not surprisingly, off label uses of Radiesse have
arisen as well. In 2007, Stupak et al described HA injection for the treatment of postrhinoplasty contour deficiences.8 Then, in 2008, after intially experimenting with
Radiesse for post-enucleation orbital augmentation9, Vagefi et al introduced the
concept of injectable osteoplasty for small frontal bone defects.10 In their novel
description, 3 patients were injected with Radiesse in conjunction with other eyelid
procedures. Subjective improvement was noted up to 7 months post-op.
To our knowledge, no one to date has examined the histologic effects of
Radiesse injection at the bony interface. In this study, we have shown that Radiesse is
biocompatable subperiosteally. The inflammatory response to both the HA and carrier
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gel was minimal. Furthermore, the HA appears long-lasting, as spherules were
identified up to 12 months post-injection. The absence of HA spherules at the
subcutaneous site for specimen 12 and at both injection sites for specimen 13 could be
indicative of resorption, but may also be explained by extrusion secondary to an error
in the injection technique. Osteoactivity was seen in at least one specimen at all time
points, indicating that new bone formation can occur as early as 1 month after
injection. Based upon this observation, the timing of sacrifice was disregarded during
statistical analysis.
In designing the study, we did consider the fact that the trauma of periosteal
disruption could trigger osteoactivity and therefore confound results. We attempted to
control for this with the carrier only injections, hypothesizing that new bone formation
would be either absent or less pronounced without HA. Unfortunately, our technique
for periosteal disruption was only successful 54% of the time. Consequently, the
numbers for truly subperiosteal HA and carrier injections were simply too low to
demonstrate a statistically significant rate of new bone formation between the two .
Notably, though, the odd of new bone formation in the subperiosteal HA injection
group was significantly higher than the aggregate of all other combinations of
injection plane and injectable. We were also able to show that the plane of injection
seems to be critical in any effort to induce osteoactivity as none of the subcutaneous
injections resulted in new bone formation, regardless of the injectable used. Lastly,
our observations suggest that, irrespective of the mechanism that triggered new bone
formation, injectable HA can be osteointegrated, as was seen with specimen 12.
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This preliminary report of subperiosteal HA (Radiesse) injection in a rat model
has verified the biocompatibility of injectable HA at the bony interface and suggested
the potential for bioactivity, specifically new bone formation. Refinements in the
technique for subperiosteal injection are clearly necessary, and further study on a
larger scale is warranted to better elucidate the stimulus for the osteoactivity we
observed histologically. Once refined, the potential for permanent bony augmentation
via transcutaneous subperiostial injections may help minimize the morbity of treating
certain craniofacial defects.
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Legends
Table 1. Summary of binary histologic data. The presence of periosteal disruption
and new bone formation is indicated with a (+). HA = hydroxylapatite (Radiesse)
Table 2. Summary of binary data for rate of new bone formation, grouped by all
combinations of injection plane and injectable. SC = subcutaneous, SP =
subperiosteal, HA = hydroxylapatite (Radiesse).
Figure 1. A. amorphous carrier gel and B. hydroxylapatite spherules shown under
high power magnification
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Figure 2. A multinucleated giant cell is depicted in the center of this high power
magnification view of a 1-month hydroxylapatite injection. Note the absence of
fibrosis
Figure 3. Under low power, subperiosteal carrier is noted to be embedded in new,
woven bone in this 6-month specimen
Figure 4. Under high power, new bone formation is seen amidst suboeriosteal
hydroxylapatite spherules in this 1-month specimen. Note the disorganized
appearance of the new, woven bone as compared to the mature lamellar bone
beneath
Figure 5. Under high power, hydroxylapatite spherules from this 12-month
specimen appear osteointegrated, with mature, lamellar bone present both below
and above the injection

Table 1

Group

1 mo

3 mo

6 mo

Specimen
#

1
2
3
4
5
6
7
8
9

Injectable

carrier
HA
HA
carrier
HA
HA
carrier
HA
HA

Subcutaneous Site

Subperiosteal Site

Periosteal
Disruption

New Bone
Formation

Periosteal
Disruption

New Bone
Formation

-

-

+
+
+
+
+
-

+
+
+
-

12

10
11
12
13
14

12 mo

carrier
HA
HA
HA
HA

Total Positives

HA not identified
+
HA not identified
+
0

0

+
+
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Table 2
New Bone Formation
Injection Plane

Injectable

SC

carrier

SC

HA

SP

carrier

SP

HA

Response

n

+
+
+
+
-

0
6
0
12
1
1
4
1
Total n = 25

Figure 1
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B.
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